Clinical trial · no report yet · Phase 1
FUMANBA-2
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
- NCT05181501 ↗
- Not yet recruiting
- Nanjing IASO Biotechnology Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)
- Phase
- Phase 1
- Status
- Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Arms
- CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- Proportion of Minimal Residual Disease (MRD)-negative subjects
- Median progression-free survival (mPFS)
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Start
- Apr 2022 (estimated)
- Primary completion
- Apr 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05181501 · updated Jan 6, 2022